Henry Schein (NASDAQ:HSIC) issued an update on its FY20 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.65 to $3.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.70. Henry Schein also updated its FY 2020
Pre-Market guidance to 3.65-3.75 EPS.
A number of equities analysts recently issued reports on the company. Evercore ISI cut Henry Schein from an in-line rating to an underperform rating in a report on Friday, January 3rd. Piper Jaffray Companies increased their target price on Henry Schein from $72.00 to $80.00 and gave the stock an overweight rating in a research note on Monday, November 11th. ValuEngine downgraded Henry Schein from a sell rating to a strong sell rating in a research report on Monday, February 10th. Barrington Research reissued a buy rating and set a $75.00 target price on shares of Henry Schein in a research note on Wednesday, November 6th. Finally, Robert W. Baird lowered shares of Henry Schein from an outperform rating to a neutral rating in a research note on Thursday, January 2nd. Five equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $72.50.
Shares of Henry Schein stock traded down $1.38 on Friday, reaching $67.54. The stock had a trading volume of 1,771,966 shares, compared to its average volume of 1,093,988. The company has a quick ratio of 0.92, a current ratio of 1.58 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $10.11 billion, a P/E ratio of 14.40, a P/E/G ratio of 2.10 and a beta of 0.85. The company has a 50 day moving average price of $69.60 and a 200 day moving average price of $65.94. Henry Schein has a 1 year low of $56.58 and a 1 year high of $73.99.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.06. Henry Schein had a return on equity of 15.01% and a net margin of 6.96%. The firm had revenue of $2.67 billion during the quarter, compared to analysts’ expectations of $2.64 billion. During the same quarter last year, the firm earned $1.12 EPS. The business’s quarterly revenue was up 7.9% on a year-over-year basis. On average, analysts forecast that Henry Schein will post 3.71 earnings per share for the current fiscal year.
Henry Schein declared that its Board of Directors has initiated a share buyback program on Thursday, October 31st that permits the company to repurchase $400.00 million in shares. This repurchase authorization permits the company to reacquire up to 4.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: Why do commodities matter?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.